MedPath

Misoprostol for the Prevention of Postpartum Hemorrhage in Rural Pakistan

Not Applicable
Completed
Conditions
Postpartum Hemorrhage
Anemia
Registration Number
NCT00120237
Lead Sponsor
Gynuity Health Projects
Brief Summary

This community-based trial will study misoprostol for the prevention of postpartum hemorrhage in rural Pakistan. Traditional birth attendants assisting home deliveries will administer study tablets (600 mcg oral misoprostol or placebo) in the third stage of labor to women participating in the trial. Blood loss, hemoglobin levels, side effects, and other variables will be evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
1600
Inclusion Criteria
  • Pregnant women in general good health, home delivery
  • Must live in one of 78 study villages
Exclusion Criteria
  • Hypertension
  • Non-cephalic presentation
  • Polyhydramnios
  • Previous cesarean section
  • Suspected multiple pregnancy
  • Suspected still birth
  • Antepartum hemorrhage
  • Previous complication in 3rd trimester
  • Anemia of <8 g/dl

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Postpartum hemorrhage (blood loss >or= 500 mL)Measured at 1 hour postpartum or until active bleeding has stopped
Drop in hemoglobin > 2 g/dL from pre to post-deliveryHemoblobin (Hb) level measured 3-5 days after delivery
Secondary Outcome Measures
NameTimeMethod
Intermediate and severe PPH (blood loss >or=750 mL and >or= than 1000 mL)Blood loss measured at 1 hr postpartum or until active bleeding stopped
Mean blood lossblood loss measured at 1 hr postpartum or until active bleeding stopped
Side effects experienced among recently delivered mothersInterviews conducted 1 day post-delivery
Anemia (<9 g/dL and <11 g/dL)Postpartum hemoglobin assessed 3 days post-delivery

Trial Locations

Locations (1)

Home delivery setting

🇵🇰

Chitral, Chitral District, Pakistan

© Copyright 2025. All Rights Reserved by MedPath